Resumen

Objectives: We assessed Glucagon-Like Pepetide-1 receptors analogs (GLP-1 RA) use, weight loss patterns, and complications among patients who underwent body contouring surgery (BCS) at our institution. Introduction: The rising use of glucagon-like peptide-1 receptor (GLP-1RA) analogs has increased interest in body contouring surgery (BCS). Materials / method: A retrospective analysis of BCS patients with GLP-1RA prescriptions was conducted. They were categorized into three Groups based on the time of medication use related to the surgery: Group 1 (preoperative use), Group 2 (pre-op and post-op use), and Group 3 (postoperative use). Every patient received a Clavien-Dindo grade per complication; each grade was converted into a continuous variable. Fisher's exact and chi-square tests analyzed categorical variables, and repeated measures ANOVA evaluated changes in medication use and body mass index (BMI) over time. Results: Forty-four patients were categorized into Group 1(n=9), Group 2 (n=9), and Group 3 (n=26).There were no statistically significant differences in demographics, BCS types and follow-up. BMI at six months after surgery was significantly lower in Groups 1 and 2 compared to Group 3 (p= 0.02). Linear regression analysis revealed that BMI at surgery strongly predicts BMI at the last follow-up, while age and medication use in Group 3 did not show significant associations. Group 2 exhibited a higher mean complication score (2.16) with a higher frequency of severe complications. Conclusion: GLP-1RA use before surgery is associated with improved weight maintenance. However, its use in the immediate perioperative period is still controversial.